Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal polysaccharide groups A, C, W‑135 and Y conjugate vaccines are quadrivalent vaccines designed to protect against invasive disease caused by *Neisseria meningitidis* serogroups A, C, W‑135 and Y. These vaccines contain purified capsular polysaccharides from each of the four serogroups covalently linked (conjugated) to a carrier protein such as diphtheria toxoid (Menactra), CRM197 (Menveo), or tetanus toxoid (MenQuadfi). Conjugation enhances immunogenicity by inducing T-cell dependent immune responses and immunological memory. The primary indication is prevention of invasive meningococcal disease in children, adolescents, and adults at increased risk due to medical conditions or exposure. The vaccines are approved for routine use in many countries for specific age groups[3][4][8].
- Brand names
- MenactraMenveoMenQuadfi
- Other names
- quadrivalent meningococcal conjugate vaccinetetravalent meningococcal conjugate vaccineNmVac4-A/C/Y/W-135
02
Targets
Neisseria meningitidis capsular polysaccharide
Beyond the preview
Go deeper on meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine.